Australia's most trusted
source of pharma news
Posted 15 January 2025 PM
An analysis of stock performance over 2024 has identified which Big Pharmas grew the most over 12 months with just over a handful ending the year better than they started and the majority going backwards - but one company was a standout doubling its stock price.
According to the figures, compiled by Swiss-based Senior Market Analyst for KBI Biopharma, Nicolas Schmitz, UCB well and truly out-performed the pack with what was described as "outstanding" sales of its anti-inflammatory drug Bimzelx, which has been PBS listed locally since last July and the company's autoimmune treatment Rystiggo which goes to the PBAC in March. UCB's stock was up 100 per cent for the year.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.